Neumora Therapeutics Fails to Meet Nasdaq Minimum Bid Price Requirement

• Neumora Therapeutics received Nasdaq notice on October 26, 2026, for failing the $1.00 minimum bid price requirement.
• The company has 180 calendar days, until April 26, 2027, to regain compliance.
• Compliance requires its common stock’s closing bid price to reach at least $1.00 for ten consecutive business days.
• A transfer to the Nasdaq Capital Market could provide additional compliance time, subject to meeting other listing requirements.
• The company is considering a reverse stock split; its common stock faces delisting if compliance deadlines, including any extensions, expire unmet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-441634), on October 30, 2026, and is solely responsible for the information contained therein.